|
KMID : 1038820170200040236
|
|
Pediatric Gastroenterology, Hepatology & Nutrition
2017 Volume.20 No. 4 p.236 ~ p.243
|
|
|
Short-Term Outcome of Infliximab Therapy in Pediatric Crohn’s Disease: A Single-Center Experience
|
|
Jung Dai
Lee Sung-Hee
Jeong In-Sook
Oh Seak-Hee
Kim Kyung-Mo
|
|
|
Abstract
|
|
|
Purpose: Studies on the efficacy of infliximab (IFX) in a large population of pediatric patients with Crohn’s disease (CD) are limited, and prognostic factors are not well-known. The aim of this study was to evaluate outcomes of IFX in pediatric patients with CD and to identify factors associated with poor prognosis.
Methods: We retrospectively analyzed medical data of 594 pediatric patients with CD between 1987 and 2013 in a tertiary center. Of these, 156 children treated with IFX were enrolled and were followed up for at least a year with intact data. Outcomes of induction and maintenance, classified as failure or clinical response, were evaluated onthe tenth and 54th week of IFX therapy.
Results: We treated 156 pediatric patients with CD with IFX, and the median duration of IFX therapy was 47 months. For IFX induction therapy, 134 (85.9%) patients experienced clinical response on the 10th week. Among the 134 patients who showed response to induction, 111 (82.8%) patients maintained the clinical response on the 54th week. In multivariate analysis, low hematocrit (p=0.046) at the time of IFX initiation was associated with the failure of IFX induction. For IFX maintenance therapy, longer duration from the initial diagnosis to IFX therapy (p=0.017) was associated with maintenance failure on the 54th week.
Conclusion: We have shown the acceptable outcomes of IFX in a large cohort of pediatric CD patients in Korea. Hematocrit and early introduction of IFX may be prognostic factors for the outcomes of IFX.
|
|
|
KEYWORD
|
|
|
Crohn disease, Child, Infliximab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|